Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024 - Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin – an investigational oral Lp(a) inhibitor – was investigated in patients with elevated Lp(a) levels and high CV risk.
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Gautam Nayak, MD
Michelle Kittleson, MD, PhD
Michelle Kittleson, MD, PhD
Kibum Kim, PhD
